PIL also seeks action against drug regulator for letting a FDA-censured firm continue operations
Pankaj Kumar | March 14, 2014
Ranbaxy faced another setback on Friday as the supreme court issued notice to the leading drugmaker as well as the central government following a PIL that seeks cancellation of the firm’s licence and a CBI probe into the allegedly sub-standard quality of its medicines.
"The matter requires consideration and we will examine it but we cannot grant any interim stay," a bench headed by chief justice P Sathasivam said.
The PIL was filed by advocate ML Sharma, pointing out that Ranbaxy was fined $500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs last year. The PIL demanded court to stop production from the manufacturing units in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.
Read more about Ranbaxy’s travails:
Sharma sought action against the drug regulator, Central Drug Standards Control Organisation (CDSCO), for granting permission to Ranbaxy to sell drugs in India though the firm has faced a series of strictures from the US FDA.
Read interview with drug controller GN Singh:
Do new norms for political donations hurt transparency?
With commissioning of 800 MW unit at Kudgi in Karnataka, 250 MW unit at Bongaigaon in Assam and 20 MW at Bhadla solar in Rajasthan, the total installed capacity of National Thermal Power Corporation (NTPC) group has reached to 49,943 MW. The 12th plan cap
Aadhaar is arguably one of the most convoluted public policy interventions in India’s history. It has been more than eight years, yet there is little clarity on the exact purpose of the biometric-based unique identification project. Let me take you through an event which I witne
The airports authority of India (AAI), a Miniratna PSU, has undertaken operation, development and maintenance of Diu airport from Diu administration. A memorandum of understanding demonstrating the responsibilities was inked on March 20 between the union terri
Central public sector enterprises (CPSEs) have done quite well despite facing headwinds, according to the Public Enterprises Survey (2015-16) that was tabled in parliament on March 21. The net worth of all the CPSEs have gone up and the overall net profit has zoomed. Their contribution to the cen
After much discussion and pondering over for more than two years, the cabinet has approved a new National Health Policy, scrapping the old one which was formulated in 2002. The government aims to increase the public health expenditure to 2.5% of the GDP by 2025. The policy formulated in 2002 aimed